A

Alpine Immune Sciences Inc
F:34LA

Watchlist Manager
Alpine Immune Sciences Inc
F:34LA
Watchlist
Price: 59 EUR Market Closed
Market Cap: 4B EUR

Relative Value

There is not enough data to reliably calculate the relative value of 34LA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

34LA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
71.1
Median 5Y
21.9
Industry
7.9
vs History
vs Industry
Median 3Y
-109.1
Median 5Y
-9.6
Industry
23.7
vs History
vs Industry
Median 3Y
-49.9
Median 5Y
-9.8
Industry
22
vs History
vs Industry
Median 3Y
-48.3
Median 5Y
-13.8
Industry
23.8
vs History
vs Industry
Median 3Y
12.1
Median 5Y
4.7
Industry
3.3
vs History
vs Industry
Median 3Y
65.7
Median 5Y
14.1
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
Median 3Y
-73.2
Median 5Y
-6.1
Industry
6.4
vs History
vs Industry
Median 3Y
-72.3
Median 5Y
-6
Industry
7
vs History
vs Industry
Median 3Y
-46.1
Median 5Y
-5.7
Industry
8.3
vs History
vs Industry
Median 3Y
-45.9
Median 5Y
-5.6
Industry
6.5
vs History
vs Industry
Median 3Y
58.2
Median 5Y
6.9
Industry
5.7

Multiples Across Competitors

34LA Competitors Multiples
Alpine Immune Sciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Alpine Immune Sciences Inc
F:34LA
3.9B EUR 80.4 -123.4 -83.5 -82.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 770 229.5 -160 504.9 -194 904.1 -192 680.1
US
Abbvie Inc
NYSE:ABBV
396.1B USD 6.6 168.7 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
176.6B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
148.6B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD 9.8 31.4 23 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.1 -532.3 -579.6 -564.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
84B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
45.1B EUR 14.7 34.6 59.7 61.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.2B USD 16.3 1 198.5 157.4 190.9
P/E Multiple
Earnings Growth PEG
US
A
Alpine Immune Sciences Inc
F:34LA
Average P/E: 189.1
Negative Multiple: -123.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 504.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
NL
argenx SE
XBRU:ARGX
34.6
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 198.5
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Alpine Immune Sciences Inc
F:34LA
Average EV/EBITDA: 39.5
Negative Multiple: -83.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 904.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
NL
argenx SE
XBRU:ARGX
59.7
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
157.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Alpine Immune Sciences Inc
F:34LA
Average EV/EBIT: 45.5
Negative Multiple: -82.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 680.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
NL
argenx SE
XBRU:ARGX
61.4
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.9
N/A N/A